Literature DB >> 29475443

Correction to: Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.

Amy Wallis1, Michelle Ball2, Henry Butt3, Donald P Lewis4, Sandra McKechnie5, Phillip Paull3, Amber Jaa-Kwee5, Dorothy Bruck2.   

Abstract

The original version of this article [1], published on 6 February 2018, contains a mistake in the 'Conclusions' section. The corrected version of the affected sentence is given below and the corrected part is marked in bold.

Entities:  

Year:  2018        PMID: 29475443      PMCID: PMC6389197          DOI: 10.1186/s12967-018-1413-y

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


Correction to: J Transl Med (2018) 16:24 10.1186/s12967-018-1392-z

The original version of this article [1], published on 6 February 2018, contains a mistake in the ‘Conclusions’ section. The corrected version of the affected sentence is given below and the corrected part is marked in bold. It is unclear whether the reduction in Streptococcus is particularly beneficial in some ME/CFS patients or whether other concurrent microbial shifts are equally or more valuable (i.e., increased and/or reduced ).
  1 in total

1.  Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.

Authors:  Amy Wallis; Michelle Ball; Henry Butt; Donald P Lewis; Sandra McKechnie; Phillip Paull; Amber Jaa-Kwee; Dorothy Bruck
Journal:  J Transl Med       Date:  2018-02-06       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.